J
Janux is a clinical-stage company developing unique immunotherapies that have the potential to generate tumor-specific immune responses to attack and kill tumors without destroying a patientβs healthy tissue. Janux is using its platform masking technology to engineer novel drug candidates that are designed to overcome the traditional T cell engager toxicity and efficacy limitations. Janux is proud to have earned a ππ«πππ ππ₯πππ ππ¨ ππ¨π«π€ πππ«ππ’ππ’ππππ’π¨π§β’ in 2024.
Investor insights
Funding rounds participated in
$350M sweet spot round size
Investor type
Public Company
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Date founded
2017
Funding rounds raised
Total raised
$350M
from investors over 1 rounds
J
Janux Therapeutics raised $350M on January 3, 2025